• F-18 Pivalate PET shows high uptake regardless of the origin of the primary tumor
  • F-18 pivalate can be used to monitor brain metastases
  • Patients without prior external irradiation show higher tumor uptake, while those previously treated show a trend toward lower uptake

Melbourne, Australia, October 18, 2022 /PRNewswire/ — Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for diagnostic and therapeutic use, is pleased to announce that F-18 pivalate (RAD 101) achieved successful phase 2a data in patients with brain metastases and demonstrated significant tumor uptake that was consistent and independent of tumor origin.

A full presentation of the results will take place on April 34th EORTC/AACR/NCI Symposium in Barcelona (26-28 October 2022). The study was funded by the Medical Research Council and will also be published in a peer-reviewed journal in due course.

“We are very excited to see a new molecule and innovative mode of action showing significant results in brain tumor metastases,” said Radiopharm’s CEO and Managing Director Riccardo Canevari.

“The team at Imperial College London led by Professor Eric Aboagye, did a great job. F-18 pivalate and its potential therapeutic variations currently under development represent a promising theranostic approach to target brain metastases and potentially other brain tumors.

“These positive and encouraging results will support accelerated future development of F-18 Pivalate and we look forward to initiating discussions with medical experts and regulatory authorities.”

Professor Aboagye from Imperial College London and principal inventor of 18-F pivalate added: “This technology has demonstrated superior imaging performance in multiple cancer types compared to the current clinical standard in PET imaging. We are very pleased that this preliminary data further confirms its potential.”

Radiopharm has acquired an exclusive worldwide license to the Pivalate platform technology from Cancer Research Technology Limited and Imperial College London and has entered into a sponsored research agreement with Professor Aboagye for new analogues.

Authorized on behalf of the Board of Directors of Radiopharm Theranostics by the Executive Chairman Paul Hopper.

For more informations:

Matt Wright
NWR communication
T: +61 451 896 420
E: [email protected]

Follow Radiopharm Theranostics:

Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked – https://www.linkedin.com/company/radiopharm-theranostics/

SOURCE Radiopharm Theranostics